Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alaunos Therapeutics Inc TCRT

Healthcare Biotechnology
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity... see more

Recent & Breaking News (NDAQ:TCRT)

ZIOPHARM to Present at the Stifel 2017 Healthcare Conference

GlobeNewswire November 10, 2017

9 Notable Biotechs Presenting At This Year's ASH Meeting

Benzinga.com  November 6, 2017

ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities

GlobeNewswire November 6, 2017

ZIOPHARM Oncology, Inc. to Host Earnings Call

Accesswire November 6, 2017

ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology

GlobeNewswire November 6, 2017

ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual Meeting

GlobeNewswire November 1, 2017

ZIOPHARM Oncology to Host Third-Quarter 2017 Financial Results and Corporate Update Conference Call on November 6, 2017 at 4:30 p.m. ET

GlobeNewswire October 26, 2017

ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors

GlobeNewswire October 16, 2017

Watch These 8 Huge Put Purchases In Friday Trade

Benzinga.com  October 13, 2017

ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology

GlobeNewswire October 12, 2017

ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer

GlobeNewswire September 28, 2017

ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting

GlobeNewswire September 18, 2017

Technical Snapshots for These Biotech Stocks -- ZIOPHARM Oncology, Zosano Pharma, Juno Therapeutics, and Lexicon Pharma

PR Newswire September 7, 2017

ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

GlobeNewswire September 5, 2017

ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit

GlobeNewswire September 1, 2017

ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities

GlobeNewswire July 31, 2017

Investor Network: ZIOPHARM Oncology, Inc. to Host Earnings Call

Accesswire July 31, 2017

ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET

GlobeNewswire July 24, 2017

ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma

GlobeNewswire June 28, 2017

12 Biggest Mid-Day Gainers For Thursday

Benzinga.com  June 22, 2017